Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(60.0%)

Phase 3

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 1(3)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00477906Phase 3Unknown

M-Vax + Low Dose Interleukin-2 Versus Placebo Vaccine in Metastatic Melanoma in Patients With Stage IV Melanoma

Role: lead

NCT00298298Phase 1Terminated

DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Role: lead

NCT00660101Phase 1Unknown

Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer

Role: lead

NCT00003715Phase 2Terminated

Vaccine Therapy Compared With Interferon Alfa in Treating Patients With Stage III Melanoma

Role: lead

NCT00257465Phase 1Completed

Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma

Role: lead

All 5 trials loaded